This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

ICD-10 G31.82 — Dementia with Lewy bodies; the dementia syndrome is additionally coded as F02.8* Special Copayment Reduction: V800

Dementia with Lewy bodies, DLB루이소체 치매

Synonyms: Lewy body dementia, Lewy body disease, diffuse Lewy body disease, DLB

ICD-10 coding guide
G31.82 is the principal diagnosis code describing the underlying neuropathological cause of dementia with Lewy bodies (Lewy body disease), and the accompanying dementia syndrome is additionally coded as F02.8* (dementia in other specified diseases). On claims, enter G31.82 F02.8* in this order; G31.82 is the principal diagnosis. The Special Copayment Reduction code is V800.
Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

The pathological origin of dementia with Lewy bodies (DLB) dates to 1912, when the German neurologist Friedrich Heinrich Lewy discovered distinctive intraneuronal inclusions (Lewy bodies) in the brains of patients with Parkinson disease. Lewy described these inclusions in the substantia nigra, basal forebrain, and several brainstem nuclei, but at the time the association between cortical Lewy body pathology and dementia was not recognized.

In 1961, Okazaki first reported widespread cortical Lewy body pathology in patients with dementia, and in the 1980s–90s Kosaka in Japan and Perry and McKeith in the UK elucidated the clinicopathological features of "diffuse Lewy body disease" through systematic clinicopathological studies. In 1996, McKeith et al. published the first edition of the international diagnostic criteria for dementia with Lewy bodies (McKeith criteria), which were subsequently revised in 2005 and 2017. That alpha-synuclein protein is the main component of Lewy bodies was revealed following Polymeropoulos's discovery of an SNCA variant in 1997. DLB is now recognized as the second most common degenerative dementia after Alzheimer disease and is classified as ICD-10 G31.82.

2. Causes

The core cause of dementia with Lewy bodies is abnormal misfolding and aggregation of alpha-synuclein protein, forming Lewy bodies and Lewy neurites within cortical neurons. Normal alpha-synuclein is encoded by the SNCA gene and is involved in synaptic vesicle trafficking and maintenance of dopamine homeostasis. Misfolded alpha-synuclein forms insoluble fibrils with a beta-sheet structure, which accumulate in the cell body to make up Lewy bodies.

In a considerable proportion of DLB, mixed pathology with coexisting Alzheimer pathology (amyloid plaques, tau NFTs) is identified. Clinical features and prognosis may differ depending on the presence of mixed pathology, and cognitive decline may be faster when coexisting Alzheimer pathology is present. Parkinson disease dementia (PDD) and DLB share the same alpha-synuclein pathology, and the "one-year rule" is used clinically to distinguish them: PDD if dementia develops more than 1 year after the onset of parkinsonian motor symptoms, and DLB if dementia develops before parkinsonian symptoms or within 1 year.

3. Genetics

Most dementia with Lewy bodies is sporadic, but several genetic causes have been identified in familial cases. Duplication, triplication, or pathogenic point variants (A53T, A30P, E46K, etc.) of the SNCA (alpha-synuclein, 4q22.1) gene can cause Parkinson disease or DLB/Lewy body disease. SNCA triplication tends to cause more severe Lewy body pathology and cortical dementia.

GBA (glucocerebrosidase, 1q22) variants are the most common genetic risk factor for DLB and Parkinson disease; GBA variant carriers have about a 5-fold increased risk of developing Lewy body pathology, with earlier onset and faster cognitive decline. Representative GBA variants include L444P and N370S. LRRK2 (leucine-rich repeat kinase 2, 12q12) variants (G2019S, etc.) are mainly associated with Parkinson disease, but dementia with Lewy bodies pathology has also been reported in some cases. APOE ε4 is associated with increased DLB risk and clinical severity by mediating coexisting Alzheimer pathology. Rarely, ATP13A2, VPS35, PARK7 (DJ-1), PINK1, and PARKIN variants are associated with the parkinsonian spectrum and Lewy body pathology.

4. General epidemiology

Dementia with Lewy bodies (DLB) is the second most common cause of degenerative dementia after Alzheimer disease, accounting for about 10–25% of all dementia. In population-based studies, prevalence is reported at about 0–5% in the population aged 65 and older and about 3.5% at age 75 and older. However, DLB tends to be underdiagnosed in clinical practice and is often misdiagnosed early on as Alzheimer disease or a psychiatric disorder. The number of prevalent cases worldwide is estimated at more than about 1.4 million.

Age of onset is mainly 65–85 years, and an incidence about 1.5 times higher in men than in women is reported. The mean age of onset is about 76 years, slightly later than for Alzheimer disease (about 73 years). In Korea, statistics for DLB alone are lacking, but analysis of National Health Insurance Service data shows an increasing trend in diagnoses of Lewy body-related dementia. Autonomic abnormalities (orthostatic hypotension, constipation, urinary dysfunction) are common as comorbid conditions, and depression, anxiety disorders, and REM sleep behavior disorder (RBD) precede or accompany the disease.

5. Pathophysiology

The core molecular pathophysiology of dementia with Lewy bodies is the prion-like propagation of alpha-synuclein. Misfolded alpha-synuclein induces misfolding of normal alpha-synuclein, and a topological progression similar to Braak staging occurs, beginning in the brainstem (medulla, locus coeruleus) and spreading gradually to the limbic system and neocortex. In DLB, Lewy body pathology extensively involves the cerebral cortex — especially the frontal, temporal, and parietal lobes and the insula — causing cortical dementia symptoms.

Damage to the dopaminergic pathway (loss of nigrostriatal dopaminergic neurons) is associated with parkinsonian syndromes, and damage to this pathway is also confirmed in DLB. Damage to the cholinergic pathway is more severe in DLB than in Alzheimer disease, with prominent loss of cholinergic neurons in the nucleus basalis of Meynert in particular, associated with cognitive fluctuation, hallucinations, and impaired attention. Damage to serotonergic and norepinephrine pathways is also associated with mood disorders and sleep disorders. Involvement of the visual cortex (occipital lobe) is the neuroanatomical basis of vivid visual hallucinations and is associated with the occipital hypometabolism that appears specifically on FDG-PET.

6. Symptoms

The clinical features of dementia with Lewy bodies (DLB) are divided into core clinical features and supportive clinical features in the revised 2017 McKeith criteria. The four core clinical features are ① fluctuating cognition: marked, variable changes in attention and level of alertness; ② recurrent well-formed visual hallucinations; ③ REM sleep behavior disorder (RBD): abnormal behavior in which dream content is acted out during REM sleep; ④ parkinsonism: bradykinesia, muscle rigidity, and postural instability.

Fluctuating cognition is the most specific feature of DLB, characterized by attention and alertness that change dramatically over time, and families or caregivers often describe it as "there are good times and bad times" or "he suddenly spaces out." Visual hallucinations are typically of people, animals, or objects that are vivid and well-formed as if real, and cases occur both where the patient recognizes them as hallucinations and where the patient does not. RBD is an important prodromal symptom that can precede the onset of DLB by decades. Autonomic abnormalities (orthostatic hypotension, constipation, sialorrhea, sweating disorders) are common, and severe hypersensitivity to antipsychotic drugs (neuroleptic hypersensitivity) is characteristic.

In cognitive decline, attention, executive function, and visuospatial function are prominent early on, and episodic memory is less impaired early on than in Alzheimer disease. However, as the disease progresses, episodic memory is also involved.

7. Signs

On neurological examination, signs of parkinsonism (bradykinesia, lead-pipe rigidity, postural instability) are found and appear earlier than in Alzheimer disease. Parkinsonism in DLB tends to be less asymmetric, to have less resting tremor, and to respond weakly to levodopa compared with typical Parkinson disease. On oculomotor examination there is no downward supranuclear palsy, but convergence insufficiency may appear.

On neuropsychological testing, attention (sustained attention, selective attention), visuospatial function (RCFT copy, clock drawing), and executive function are impaired earlier than in Alzheimer disease, while verbal memory is relatively preserved. The Mayo Fluctuation Questionnaire and Clinician Assessment of Fluctuation Scale are used to assess cognitive fluctuation. Autonomic function testing confirms orthostatic hypotension (systolic blood pressure fall of 20 mmHg or more within 2 minutes) and reduced heart rate variability. On polysomnography (PSG), RBD can be confirmed when limb movements are observed during REM sleep without loss of muscle tone (REM atonia).

8. Screening

For screening of DLB, an approach that systematically evaluates cognitive fluctuation, visual hallucinations, RBD, and parkinsonism is needed. The Mayo Sleep Questionnaire (MSQ) is a caregiver-report tool for RBD screening that can be administered quickly. The Cognitive Fluctuation Scale (CFS) and Clinician Assessment of Fluctuation are used for screening cognitive fluctuation. In cognitive screening, the MoCA reflects the visuospatial, attention, and executive function deficits of DLB more sensitively than the MMSE, and the Clock Drawing Test conveniently screens for visuospatial executive function decline.

Systematic history taking regarding a history of antipsychotic hypersensitivity, history of falls, autonomic symptoms (orthostatic hypotension, constipation, urinary dysfunction), and sleep disorders (RBD features) is included in the screening process. For imaging screening, a global atrophy pattern on brain MRI (mild medial temporal lobe atrophy compared with Alzheimer disease), an occipital hypometabolism pattern together with parieto-temporal hypometabolism on FDG-PET, and reduced striatal dopamine transporter binding on dopamine transporter SPECT (DAT-SPECT) strongly support DLB. DAT-SPECT shows high sensitivity (about 78%) and specificity (about 90%) for differential diagnosis between DLB and Alzheimer disease.

9. Diagnosis

Clinical diagnosis of dementia with Lewy bodies follows the revised 2017 McKeith criteria (Fourth consensus report of the DLB Consortium, McKeith et al., 2017). A diagnosis of probable DLB applies when (A) two or more core clinical features, or (B) one core clinical feature plus one or more indicative biomarkers, are met. Possible DLB applies when there is only one core clinical feature, or only one or more indicative biomarkers.

Indicative biomarkers are ① reduced striatal dopamine transporter binding on DAT-SPECT or PET, ② RBD with loss of REM atonia confirmed on polysomnography (PSG), and ③ reduced cardiac sympathetic uptake on MIBG myocardial scintigraphy. Supportive biomarkers include preservation of medial temporal lobe structures on MRI (mild medial temporal lobe atrophy), occipital hypometabolism on FDG-PET, and posterior slow-wave activity with pre-alpha frequency activity on EEG.

Among CSF biomarkers, a positive alpha-synuclein RT-QuIC (real-time quaking-induced conversion) test shows high specificity for confirming DLB and Parkinson disease, and clinical introduction is under way. A positive brain amyloid PET confirms coexisting Alzheimer pathology, which is associated with the rate of cognitive decline. Histopathological confirmation is made at autopsy or biopsy by identifying cortical Lewy bodies and Lewy neurites with α-synuclein immunohistochemistry.

10. Treatment

There is currently no disease-modifying treatment for dementia with Lewy bodies, and treatment centers on individualized symptomatic therapy for each symptom. For improving cognitive function, cholinesterase inhibitors (rivastigmine, donepezil) have evidence in DLB for relieving impaired attention, visual hallucinations, and cognitive fluctuation, and the AChEI effect is especially pronounced in DLB because of a more severe cholinergic deficit than in Alzheimer disease. Rivastigmine has a licensed indication in Parkinson disease dementia and is also used empirically in DLB. Memantine is also used in moderate-to-severe DLB, in combination with an AChEI or alone.

For treatment of parkinsonism, levodopa is the first-line drug, but in DLB its effect is weaker than in typical Parkinson disease and it may cause the adverse effect of worsening hallucinations. Use of the lowest effective dose possible is recommended. In treatment of visual hallucinations and psychobehavioral symptoms, DLB may show severe antipsychotic hypersensitivity (neuroleptic hypersensitivity) — abrupt worsening of parkinsonian symptoms, decreased consciousness, muscle rigidity, and autonomic instability — to dopamine-blocking drugs (typical and some atypical antipsychotics), so their use is in principle prohibited or requires extreme caution. When unavoidable, low-dose quetiapine or clozapine is used empirically. For treatment of RBD, low-dose clonazepam or melatonin is used. For orthostatic hypotension, increased fluid intake, compression stockings, fludrocortisone, and midodrine are used.

11. Prognosis

Dementia with Lewy bodies is a progressive neurodegenerative disease with a generally poor prognosis. The median survival from diagnosis to death is about 6–8 years, similar to or somewhat shorter than Alzheimer disease. However, complications such as fall-related fractures, abrupt deterioration due to antipsychotic hypersensitivity, and pneumonia contribute to earlier death. Variability in neuropsychological level is large, and acute deterioration episodes may recur.

GBA variant carriers have a lower age of onset, faster cognitive decline, and a worse prognosis. Coexisting Alzheimer pathology (amyloid PET positive) is associated with faster cognitive decline. For tracking functional level, the Clinical Dementia Rating (CDR), MMSE/MoCA, and Unified Parkinson's Disease Rating Scale (UPDRS) Part III (motor function) are used in combination. Elevated plasma NfL is associated with rapid progression and is being studied as a prognostic biomarker. Prevention of treatable complications (falls, aspiration pneumonia, pressure ulcers, urinary tract infections), avoidance of antipsychotics, and linkage to palliative care are key to improving prognosis.

12. Prevention

There is no established primary prevention for dementia with Lewy bodies. In GBA variant or SNCA variant carriers, family genetic counseling and predictive testing can be offered after the proband is identified, but counseling with a mental health professional should come first. Patients diagnosed with RBD are a high-risk group for synucleinopathies such as DLB, Parkinson disease, and multiple system atrophy, and regular follow-up and participation in early-intervention clinical studies are recommended.

Clinical trials of preemptive alpha-synuclein aggregation-inhibiting treatment (preclinical synucleinopathy intervention) targeting GBA variant carriers and RBD patients are being planned. For maintaining general brain health, management of cardiovascular risk factors, regular exercise, prevention of head trauma, and increased social participation are recommended. Management of orthostatic hypotension, fall prevention education, creating a safe home environment, and education of medical staff about antipsychotic hypersensitivity are key safety education items for the multidisciplinary team immediately after a DLB diagnosis.

13. References